HR10185

On August 31, 2026, Rep. Gus Bilirakis (R-FL) introduced HR10185, a bill requiring the Secretary of Health and Human Services to establish a temporary premium credit for enrollees in Medicare Part D prescription drug plans. The bill has been referred to the House Energy and Commerce and Ways and Means Committees. As an early-stage authorization bill, it does not appropriate any funds; actual spending would require a separate appropriations step. The mechanism is a premium credit, meaning the government would subsidize Part D premiums for eligible enrollees, reducing their out-of-pocket costs. This directly affects Medicare Part D plan sponsors, primarily large insurers and PBMs. UnitedHealth Group and CVS Health ($CVS) are the two largest Medicare Part D plan providers. For these companies, the credit could reduce per-member premium revenue but potentially increase enrollment and prescription volume. The net financial impact is ambiguous without knowing the credit's size, duration, and eligibility criteria. The bill's sponsor is a junior member, not a committee chair, which reduces legislative momentum. No companion bill in the Senate has been introduced. The legislative path includes committee hearings, markups, floor votes, and Senate action—all unlikely in the near term given the 119th Congress's remaining calendar. Investors should monitor committee activity and any CBO score for cost estimates. Without a funding source, the bill faces significant hurdles.